insulin degludec vs Insulin glargine (Basaglar)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin degludec · Tresiba
Marketed by Novo Nordisk
NCT00982644 · Phase 3 · completed
The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)
Result source: NCT00982644
Insulin glargine (Basaglar)
Marketed by Eli Lilly and partners
NCT01421459 · Phase 3 · completed
The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)
Result source: NCT03338010
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin degludec | Insulin glargine (Basaglar) |
|---|---|---|
| HbA1c, change | -0.1% vs -0.1%vs NovoRapidNCT0326800522 other results
| -1.3% vs -1.3%vs LantusNCT014214599 other results
|
| Body weight, change (kg) | 1.2 vs 1.1vs NovoRapidNCT0326800515 other results
| 1.6 vs 1.9vs LantusNCT014214597 other results
|
| HbA1c below 7% | 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116 | 43.7% vs 44.9%vs Lantus®NCT03338010 |
| Fasting plasma glucose, change | -3.9 vs -3.7vs Insulin GlargineNCT0250116115 other results
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT05802862 | —Not reported |
HbA1c, change
- insulin degludec
- -0.1% vs -0.1%vs NovoRapidNCT03268005
22 other results
- -1.1% vs -1.2% NCT00982644
- -0.6% vs -0.5% NCT04588259
- -0.1% vs -0.1% NCT01570751
- -1.4% vs -1.6% NCT04795531
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.5% vs -1.4% NCT02762578
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -1.3% vs -0.4% NCT01676116
- -1.1% vs -1.1% NCT02648217
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -0.9% vs -0.8% NCT01959529
- -2.0% vs -1.7% NCT02501161
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -0.5% vs -0.5% NCT03078478
- -0.9% vs -1.1% NCT00982644
- -0.5% vs 0% NCT04538352
- Insulin glargine (Basaglar)
- -1.3% vs -1.3%vs LantusNCT01421459
9 other results
- -1.3% vs -1.2% NCT02302716
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.3% NCT01421459
- -1.1% vs -1.1% NCT01421459
- -1.3% vs -1.4% NCT01421459
- -0.9% vs -0.9% NCT01421459
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.2% NCT03338010
- -0.5% vs -0.5% NCT01421459
Body weight, change (kg)
- insulin degludec
- 1.2 vs 1.1vs NovoRapidNCT03268005
15 other results
- 2.3 vs 2.8 NCT04795531
- 0.2 vs -2.5 NCT03172494
- 0.5 vs 2.2 NCT02501161
- 2.8 vs 2.2 NCT02762578
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- -1.4 vs 1.8 NCT01952145
- 2.9 vs -1 NCT02607306
- 4.1 vs -1 NCT02607306
- 2.9 vs 1.7 NCT03078478
- 1.3 vs -2.5 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 2 vs -0.8 NCT01676116
- 1.2 vs 3 NCT02501161
- -8.6 vs 1.4 NCT04538352
- Insulin glargine (Basaglar)
- 1.6 vs 1.9vs LantusNCT01421459
7 other results
- 1.3 vs 1.4 NCT01421459
- 1.7 vs 2.2 NCT01421459
- 1.0 vs 1.2 NCT01421459
- 1.9 vs 2.2 NCT01421459
- 2.3 vs 1.7 NCT02302716
- 1.1 vs 1.2 NCT03338010
- 0.3 vs 0.5 NCT01421459
HbA1c below 7%
- insulin degludec
- 75.3% vs 35.6%vs Liraglutide or ExenatideNCT01676116
- Insulin glargine (Basaglar)
- 43.7% vs 44.9%vs Lantus®NCT03338010
Fasting plasma glucose, change
- insulin degludec
- -3.9 vs -3.7vs Insulin GlargineNCT02501161
15 other results
- -2.0 vs -1.4 NCT03078478
- -4.1 vs -2.6 NCT02607306
- -4.0 vs -2.6 NCT02607306
- -3.0 vs -3.0 NCT04795531
- -3.6 vs -1.9 NCT03172494
- -4.0 vs -3.8 NCT02501161
- -3.0 vs -0.6 NCT01676116
- 0.6 vs 0.7 NCT03268005
- -3.5 vs -1.9 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -3.0 vs -1.6 NCT02762578
- -2.8 vs -2.3 NCT02911948
- 0.4 vs 0.2 NCT04588259
- -0.8 vs 0 NCT01570751
- -2 vs -4.4 NCT02648217
- Insulin glargine (Basaglar)
- —Not reported
3-point MACE (% with event)
- insulin degludec
- —Not posted · NCT05802862
- Insulin glargine (Basaglar)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. insulin degludec: 6 of 6 rows · Insulin glargine (Basaglar): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin degludec Rows use multiple source trials | Insulin glargine (Basaglar) Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=200) @ 32wka,b,c,d,e NCT02298192 · Phase 3 · registry result, not featured evidence show 1 more dose-2.01% (n=189) @ 32wk NCT02298192 · Phase 3 · registry result, not featured evidence | -0.86% (n=259) @ 24wkb,c,d,e NCT04153981 · Phase 4 · registry result, not featured evidence |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants | 63% (n=292) vs 22.6% (n=146) Liraglutide or Exenatide @ 26wkc,f,g NCT01676116 · Phase 3 · registry result, not featured evidence · combination | 23.4% (n=334) vs 16.5% (n=158) Lantus® @ 24wkc,f,g NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Dropout rate | 21.5%once dailyh NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results2% NCT01959529 · Phase 3 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence 2.7% NCT04795531 · Phase 3 · registry result, not featured evidence 6.7%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence 2.7% NCT03268005 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 2.2% NCT02906917 · Phase 3 · registry result, not featured evidence 8.5%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 4.2%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 7.6%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence | 11.9%i NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results7.6% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.4% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 2.6%once dailyh NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results0% NCT01959529 · Phase 3 —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination — NCT03336528 · Phase 4 · registry result, not featured evidence — NCT04588259 · Phase 3 · registry result, not featured evidence — NCT04795531 · Phase 3 · registry result, not featured evidence 0.6%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence — NCT03078478 · Phase 3 · registry result, not featured evidence — NCT03268005 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence 0.4% NCT02906917 · Phase 3 · registry result, not featured evidence 2.2%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.3%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 0%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence 0.3%Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination —Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination — NCT01570751 · Phase 3 · registry result, not featured evidence | 1.6%i NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results0.4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT04153981 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 15.1%once dailyh NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 25 more results38.6% NCT01959529 · Phase 3 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 3.7% NCT03336528 · Phase 4 · registry result, not featured evidence 6.7% NCT04588259 · Phase 3 · registry result, not featured evidence 5.1% NCT04795531 · Phase 3 · registry result, not featured evidence 4%Insulin Degludec NCT03172494 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 20.8% NCT03078478 · Phase 3 · registry result, not featured evidence 7% NCT03268005 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 6.8% NCT02906917 · Phase 3 · registry result, not featured evidence 4.8%Insulin Degludec NCT02607306 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.4%BID NCT02762578 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 3.8%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence —Insulin Degludec/Liraglutide + Ora NCT01676116 · Phase 3 · registry result, not featured evidence · combination 3.1%Insulin Degludec/Liraglutide +OADs NCT01676116 · Phase 3 · registry result, not featured evidence · combination 2.9% NCT01570751 · Phase 3 · registry result, not featured evidence | 4%i NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | once dailyh nasopharyngitis 23.9% headache 13.8% diarrhoea 10.8% NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 23 more resultsonce weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination emergency room visit for bilateral knee pain 1.2% emergency room visit for congestive heart failure 1.2% emergency room visit for wound infection 1.2% NCT03336528 · Phase 4 · registry result, not featured evidence diabetic retinopathy 14.7% hyperlipidaemia 14% upper respiratory tract infection 9.3% NCT04588259 · Phase 3 · registry result, not featured evidence covid-19 4.8% influenza 3.1% diabetic retinopathy 2% NCT04795531 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.7% nasopharyngitis 5.1% diabetic retinopathy 3.4% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence nasopharyngitis 19% upper respiratory tract infection 18.1% diarrhoea 9% NCT03078478 · Phase 3 · registry result, not featured evidence nasopharyngitis 5.9% NCT03268005 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.2% back pain 6% NCT02906917 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 33.6% weight increased 7% pharyngitis 5.5% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence BID upper respiratory tract infection 21.1% diabetic retinopathy 10% viral upper respiratory tract infection 2.5% NCT02762578 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence twice daily blood glucose decreased 35.4% upper respiratory tract infection 6.2% pyrexia 3.1% NCT02648217 · Phase 3 · registry result, not featured evidence lipase increased 10% headache 9.3% nasopharyngitis 8.9% NCT01676116 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 1.4% NCT01570751 · Phase 3 · registry result, not featured evidence | i nasopharyngitis 5.6% upper respiratory tract infection 5.1% abnormal weight gain 2.7% NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more resultsnasopharyngitis 7.2% upper respiratory tract infection 4% weight increased 3.2% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 upper respiratory tract infection 20.3% hypertension 5.6% injection site pain 4.2% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 32 weeks versus 24 weeks.
- fTreatment context differs: combination versus monotherapy.
- gAssessment timepoints differ: 26 weeks versus 24 weeks.
- hPopulation comparability has not been reviewed for 25 of these studies.
- iPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin degludec
show 2 more results
+ 106 further endpoints in the CSV export.
Insulin glargine (Basaglar)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · Insulin glargine (Basaglar)'s landscape